RxDoctor Payments Data

Ajay Rathore, MD

Nephrology · Newport News, VANPI 1023372679

Payments from drug & device makers

$807in general payments, 2019–2025

Across 18 payments — averaging $44.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$197
  • AstraZeneca$140
  • Amgen$125
  • Novartis$114
  • W. L. Gore & Associates, Inc.$102
  • Fresenius USA Marketing, Inc.$37
  • plus $91 from 4 others

What the payments were for

  • Food & beverage$68284%
  • Education$12516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$807 in reported general payments places this provider in the 45th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$168,273
Medicare patients
313
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide30$113,545
AuryxiaFerric Citrate28$78,606
Sevelamer Carbonate64$15,012
LokelmaSodium Zirconium Cyclosilicate60$9,885
Torsemide86$1,912
Calcitriol107$1,131
Hydralazine Hcl71$1,112
Bumetanide30$924
Metoprolol Succinate68$690
Doxazosin Mesylate68$614
Carvedilol121$580
Potassium Chloride56$561
Furosemide162$538
Gentamicin Sulfate18$519
Amlodipine Besylate173$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$37$113,54530 claims
AstraZenecaLokelma$140$9,88560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 298 nephrology providers in Virginia.

Other nephrology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →